San Diego drugmaker Ligand Pharmaceuticals has entered into a licensing agreement with San Francisco-based Tizona Therapeutics.

Under the terms of the agreement, Tizona will use three of Ligand’s animal platforms for producing human therapeutic antibodies (which can be used to develop drugs that boost the body’s immune response). Ligand’s animal platforms involve transgenic mice and rats that contain genetic material into which DNA from an unrelated organism has been artificially introduced.

The three models are collectively called OmniAb, and contain OmniRat, OmniMouse and OmniFlic.

Ligand will be eligible to receive annual “platform access” payments as well as patent filing fees, clinical milestone payments, and royalties for each successful OmniAb antibody. Tizona will be responsible for all costs related to the program, according to a Ligand news release.

This is the second OmniAb licensing deal struck by Ligand, said John Higgins, CEO of Ligand. The company now has 18 commercial partners overall.